GC Biopharma Corp. (KRX:006280)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Manufacturing and Sales of Pharmaceuticals, Etc.	1.98T	1.58T	1.44T	1.48T	-
Manufacturing and Sales of Pharmaceuticals, Etc. Growth	25.40%	9.72%	-2.94%	-	-
Diagnosis and Analysis of Samples, Etc.	181.90B	200.12B	213.76B	262.18B	-
Diagnosis and Analysis of Samples, Etc. Growth	-9.10%	-6.38%	-18.47%	-	-
Other	14.15B	16.06B	18.50B	22.10B	-
Other Growth	-11.92%	-13.17%	-16.29%	-	-
Consolidation Adjustment	-187.31B	-117.27B	-46.49B	-57.45B	-
Energy Storage Device Manufacturing and Sales	-	-	-	-	1.54T
Total	1.99T	1.68T	1.63T	1.71T	1.54T
Total Growth	18.54%	3.27%	-4.95%	11.28%	2.24%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
South Korea	1.55T	1.42T	1.40T	1.46T	9.50B
South Korea Growth	9.58%	1.16%	-4.23%	15297.99%	-99.26%
Overseas	626.44B	380.65B	272.87B	306.71B	39.46B
Overseas Growth	64.57%	39.50%	-11.03%	677.21%	-85.48%
Consolidation	-187.31B	-117.27B	-46.49B	-57.45B	-
Total	1.99T	1.68T	1.63T	1.71T	48.96B
Total Growth	18.54%	3.27%	-4.95%	3395.47%	-96.75%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 25, 2026

Data Sources Report a data error